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Abstract
Insulin resistance is closely related to intramyocellular lipid (IMCL) accumulation, and both are 
associated with increasing age. It remains to be determined to what extent perturbations in IMCL 
metabolism are related to the ageing process per se. On two separate occasions whole-body and 
muscle insulin sensitivity (euglycaemic hyperinsulinaemic clamp with 2-deoxyglucose) and fat 
utilisation during 1 h of exercise at 50% VO2max ([U-13C]palmitate infusion combined with 
electron microscopy of IMCL) were determined in young lean (YL), old lean (OL), and old 
overweight (OO) males. OL displayed comparable IMCL content and insulin sensitivity to YL, 
whereas OO were markedly insulin resistant and had over 2-fold greater IMCL in the 
subsarcolemmal (SSL) region. Indeed, whereas the plasma free fatty acid rate of appearance and 
disappearance was twice that of YL in both OL and OO, SSL only increased during exercise in 
OO. Thus, skeletal muscle insulin resistance and lipid accumulation often observed in older 
individuals are likely due to lifestyle factors, rather than inherent ageing of skeletal muscle as 
usually reported. However, age per se appears to cause exacerbated adipose tissue lipolysis, 
suggesting that strategies to reduce muscle lipid delivery and improve adipose tissue function may 
be warranted in older overweight individuals.
The global prevalence of type 2 diabetes is most apparent in older people (1), and it is estimated 
that the number of people over 65 years of age with diabetes will have increased 4.5 fold by 2050 
(2). Gaining mechanistic insight of age related insulin resistance and strategies to improve insulin 
sensitivity with age are clearly warranted. Although ageing is associated with insulin resistance, 
age per se does not appear to cause insulin resistance (3, 4, 5). Several factors that likely contribute 
to age related insulin resistance include increased abdominal adiposity and reduced physical 
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activity (3, 4), along with declines in muscle mass (6, 7). Of note, intramyocellular lipid (IMCL) 
accumulates with age, particularly in subsarcolemmal (SSL) regions (8), and has been strongly 
associated with insulin resistance (9, 10, 11, 12). Indeed, SSL lipid accumulation has been linked 
to the accumulation of metabolites, such as diacylglycerol (DAG) and ceramide, thought by some 
(13, 14, 15), but not others (16), to contribute to impaired insulin-stimulated muscle glucose 
uptake. Nevertheless, it remains contentious as to which factors associated with age influence 
IMCL accumulation.
The accumulation of IMCL and associated metabolites likely result from an imbalance between 
muscle lipid delivery and oxidation. Indeed, studies have demonstrated reduced free fatty acid 
(FFA) oxidation in older people compared to young, despite whole-body lipolysis and plasma FFA 
availability being greater at rest and during exercise at the same absolute and relative intensities 
(17, 18). Linked to this, several studies have suggested age related blunting of FFA oxidation and 
increased IMCL accumulation are a result of reduced muscle mitochondrial content (8) and 
function (3, 19, 20) with age. However, increased adiposity and reduced habitual levels of physical 
activity also affect FFA flux and oxidation in older individuals (21), and studies to date have not 
controlled for these factors when investigating changes in muscle IMCL metabolism with age. 
Therefore, we investigated the effect of ageing on whole-body and skeletal muscle lipid 
metabolism, with parallel characterization of muscle insulin sensitivity, in lean young and older 
individuals matched for estimated habitual physical activity levels and body composition. To 
determine the effect of adiposity and reduced physical activity on the ageing process, the older 
lean individuals were also compared to a group of older overweight individuals matched for lean 
mass. We hypothesized that an age-associated imbalance between FFA delivery and oxidation in 
skeletal muscle during exercise would only be observed in older overweight individuals, which 
would manifest as reduced IMCL oxidation and increased IMCL storage, particularly in the SSL 
region, and be associated with skeletal muscle insulin resistance.
Research Design and Methods
Subjects
Seven young lean, (YL; BMI <25 kg/m-2), old lean (OL; body mass index (BMI) <25 kg/
m-2), and old overweight (OO; BMI >27 kg/m-2) healthy, recreationally active male 
volunteers participated in the present study, which was approved by the University of 
Nottingham’s Medical School Ethics Committee in accordance with the Declaration of 
Helsinki. Before taking part, all subjects underwent routine medical screening and 
completed a quality of life (SF-36) questionnaire indicating their ability to perform physical 
activity. They also completed a general health questionnaire indicating their habitual 
frequency of performing moderate to high intensity physical activities including team sports, 
resistance exercise, running, cycling, and swimming (Table 1). Informed consent was 
obtained from all volunteers before participating in the study and they were made aware that 
they were free to withdraw at any point. On a separate visit all subjects performed an 
incremental exhaustive exercise test on an electronic-braked cycle ergometer (Excalibur, 
Lode, The Netherlands) to determine their maximal rate of oxygen consumption (VO2max; 
Quark CPET, Cosmed, Italy) and the workload that would elicit 50% VO2max, which was 
confirmed in a familiarization visit at least 3 days later.
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Experimental Protocol
Subjects attended the laboratory on two occasions separated by at least 1 week. On the first 
occasion they arrived at 0800 after an overnight fast, having abstained from exercise and 
alcohol for the previous 48 hours, in order to determine their body composition and insulin 
sensitivity. Trunk, leg and arm composition using standardized regions were analyzed by a 
single operator using dual energy x-ray absorptiometry (DEXA; Lunar Prodigy, GE 
Healthcare, US). Subjects then rested semi-supine on a bed and underwent a 3 h 
euglycaemic (4.5 mmol/L) hyperinsulinaemic (60 mU·m-2·min-1) clamp (22) in combination 
with the intravenous infusion of 2-deoxy-D-glucose (2DG; 6 mg·kg-1·h-1) to assess whole 
body and skeletal muscle insulin sensitivity, respectively. 2DG is a glucose analogue that 
closely resembles glucose in the characteristics of its transport but is metabolized by muscle 
to the 6-phosphate derivative (2DG6P). Thus, muscle 2DG6P is effectively trapped and its 
content can be determined as a direct measure of muscle glucose uptake (23). Indirect 
calorimetry (GEMNutrition Ltd, UK) was performed prior to and after 2 h of the clamp.
On the second visit, volunteers again reported to the laboratory following an overnight fast 
and rested semi-supine on a bed for infusion of NaH13CO3 (Cambridge Isotope 
Laboratories, USA) and [U-13C]palmitate (99% enriched; Cambridge Isotope Laboratories, 
USA) bound to 4.5% human serum albumin (Zenalb 4.5, Bio Products Laboratory Limited, 
UK) at a ratio of approximately 3:1 (1.94:0.64 μmol/L). Following a 63.75 μg/kg bolus of 
NaH13CO3 to prime the bicarbonate pool (24), [U-13C]palmitate was infused at a rate of 
0.19 mg·kg-1·h-1for 2 h, which then increased to 0.28 mg·kg-1·h-1 at the onset of 1 h cycling 
exercise at 50% VO2max.
Sample collection and analysis
During the first visit arterialized-venous blood (25) was obtained before and every 5 min 
throughout the clamp for measurement of blood glucose concentration (Stat Analyzer, YSI 
Inc, USA) and every 30 min throughout the clamp for subsequent analysis of serum insulin 
using a solid-phase 125I radioimmunoassay kit (Human Insulin Assay, Merck Millipore, 
USA), and plasma 2DG via gas-chromatography mass-spectrometry (GC-MS; MD800, 
Fisons, UK; 23). Needle biopsy samples were obtained from the vastus lateralis (26) before 
and immediately after the clamp and snap frozen in liquid nitrogen. At a later date, 30 mg of 
wet muscle was pulverized for analysis of 2DG6P content using a commercial 
spectrophotometric kit method (Cosmo Bio Ltd, Japan; 27). In addition, approximately 20 
mg of wet muscle from the baseline biopsy was used to determine muscle citrate synthase 
(CS) maximal activity spectrophotometrically (28) and carnitine palmitoyltransferase 1 
(CPT1) maximal activity using a radioisotope assay (29). Total RNA was also extracted 
from approximately 20 mg of wet muscle tissue (Trizol reagent; Invitrogen Ltd, UK) and 
following generation of first-strand cDNA (Superscript III kit; Invitrogen Ltd, UK), the 
relative abundance of mRNA of 12 genes from pathways involved in FFA oxidation and 
IMCL metabolism was determined using RT-PCR microfluidic cards (Applied Biosystems, 
USA, 29).
On the second experimental visit, blood samples were obtained before and every 10 min 
during exercise, analyzed immediately for blood lactate concentration (2300 Stat Analyzer; 
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YSI Inc, USA) and, following centrifugation, plasma was stored at -80°C. Plasma treated 
with tetrahydrolipostatin (30 μg/mL plasma) was analyzed for total FFA (NEFA C kit, 
WAKO Chemicals, Germany) on an automated analyzer (ABX Pentra 400, Horiba Medical 
Ltd., France). Plasma separated from EGTA treated blood was analyzed for 
[U-13C]palmitate and palmitate by TSQ triple quadrupole gas-chromatography-mass-
spectrometry/mass spectrometry (GC-MS/MS, Thermo, UK) and GC-MS (MD800, Fisons, 
UK ) respectively, after addition of a heptadecanoic internal standard and derivatization to 
their methyl esters (30). High-performance liquid-chromatography (HPLC) with 
electrochemical detection was used to measure plasma epinephrine and norepinephrine 
concentrations (31). Breath samples were also collected every 10 min during exercise via 
one-way valve bags and introduced into vacuumed glass tubes (Exetainer, Labco Ltd, UK) 
for subsequent 13CO2 enrichment analysis by continuous-flow isotope-ratio MS (CF-IRMS; 
AP2003 Breath Gas System, Analytical Precision, UK; 32). During the last 10 min of 
exercise when the 13CO2 production was at a steady-state and therefore no longer being 
retained by the muscle (negating the requirement for an acetate recovery factor), indirect 
calorimetry was performed (Quark CPET system, Cosmed, Italy). In addition, a vastus 
lateralis needle biopsy (26) was obtained immediately before and after the exercise bout and 
processed within 10 seconds to minimise ex vivo changes in intracellular metabolism and 
contamination of the IMCL pool by extracellular adipocytes. A 5 mg portion buffered in ice-
cold 3% gluteraldehyde/0.1 M sodium cacodylate (pH 7.4) and stored at 4°C for subsequent 
electron microscopy processing, and the remainder immediately frozen in lipid nitrogen. 
Samples for transmission electron microscopy were fixed in 1% osmium tetroxide, 
dehydrated in graded ethanol series and embedded in two resin blocks. Three ultrathin 70-90 
nanometer sections were cut from each block, mounted on copper grids, and stained in 
uranyl acetate and lead acetate, with one section randomly selected to be visualized at x4200 
magnification. Approximately 40 fields of view from up to 40 longitudinal fibres were 
systematically randomly selected by a blinded operator using the corners of copper grid 
squares as a guide. This method obtained at least 6 images per sample containing a SSL 
region, which was required for reproducible estimation of IMCL droplet (LD) 
characteristics. Images were analyzed using Image J to determine percentage of 
intermyofibrillar (IMF) and SSL area covered by LD, LD size, and total number of LD per 
square micrometer of local tissue area, which have been previously shown (8) to produce 
values similar to 3D stereology volume estimates (33). In addition, a portion of the pre-
exercise biopsy was freeze-dried, dissected free of visible blood and connective tissue, 
pulverized and used for the quantification of DAG and ceramide. Briefly, 50 ng internal 
standard (1,3[d5]-15:0 DAG) was added to 5 mg muscle, from which total muscle lipids 
were extracted in CHCl3:MeOH:H2O and the most abundant DAG (diC16:0, C16:0/C18:1, 
diC18:1) and ceramide (C16:0, C18:0, C18:1, C20:0, C24:1, C24:0) species were quantified 
by LC-MS-MS (Quattro Ultima, Micromass Ltd, UK; 34, 35). Peak areas were normalised 
to the internal standard and converted to absolute concentrations using a standard curve 
specific for each species. A further portion of muscle powder was also used for the 
determination of muscle creatine, phosphocreatine, glycogen, lactate, and acetylcarnitine as 
previously described (36).
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Calculations
Insulin sensitivity index (SIClamp) was calculated using the equation of Matsuda and 
DeFronzo (SIClamp = M/(G × ΔI); 22) where steady-state (120-180 min) glucose disposal 
(M) is normalized for steady-state blood glucose concentration (G; mmol/L) and the 
difference between fasting and steady-state plasma insulin concentrations (ΔI; mU/L). 
Indirect calorimetry calculations both at rest and during exercise were performed according 
to non-protein stoichiometric equations (37) and normalised to lean body mass (DEXA). 
The rate of appearance (Ra), disappearance (Rd), and oxidation of palmitate during the final 
10 min of exercise were used to calculate total plasma FFA kinetics by dividing the 
fractional contribution of plasma palmitate to total plasma FFA concentration as previously 
described (38). The contribution of other fat sources was calculated by subtracting plasma 
FFA oxidation from total fat oxidation calculated via indirect calorimetry.
Statistical Analysis
Differences between groups at baseline, and within and between groups during exercise, 
were analyzed using a one- and two-way ANOVA, respectively (GraphPad Prism 6.0, 
GraphPad Software Inc, USA). When a significant main effect was observed, Tukey’s and 
Sidak’s post-hoc test was performed, respectively, to identify individual differences. 
Statistical significance was set at P<0.05, and all values are presented as means ± SEM.
Results
Subject characteristics
In line with the inclusion criteria OL and YL had a similar body composition. However, OO 
had greater trunk, arm and leg fat masses compared with OL and YL subjects, but similar 
whole-body, arm and leg fat free mass (Table 1). Furthermore, self-reported levels of 
habitual physical activity were similar between OL and YL, but less in OO compared to OL. 
Both OL and OO had similar absolute (mL/min) and relative (mL·kg lbm-1·min-1) VO2max 
but these were less than in YL, as were the corresponding absolute workload and heart rate 
at 50% VO2max.
Skeletal muscle insulin sensitivity and lipid metabolite content
Steady-state serum insulin and glucose disposal during the euglycaemic hyperinsulinaemic 
clamp for OL, YL, and OO were (119.6 ± 7.0, 117.7 ± 7.8, and 137.5 ± 4.3 mU/L) and (57.8 
± 5.6, 65.1 ± 5.6, and 41.6 ± 5.2 μmol·kg lbm-1·min-1; P<0.01 OL and YL vs. OO), 
respectively. As such, OL and YL had similar SIClamp that were 57% (P<0.05) and 86% 
(P<0.01) greater than OO, respectively (Figure 1A). Furthermore, muscle 2DG6P 
accumulation during the clamp was not different between OL and YL, but was less than half 
that of YL in OO (P<0.01; Figure 1B), and OL and YL had similar steady-state plasma 2DG 
concentrations during the clamp, which were less than OO (50.0 ± 1.9 and 48.8 ± 2.2 vs. 
72.6 ± 2.2 μmol/L, respectively; P<0.05; Figure 1C). Insulin-stimulated resting energy 
expenditure increased by more than 10% in both OL (P<0.01) and YL (P<0.05), but did not 
change in OO (P=1.0; Figure 1D). There were no differences in muscle DAG species 
between groups with the exception of diC18:1, which was lower in OL and YL compared to 
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OO (both P<0.05; Figure 2A). Similarly most muscle ceramide species did not differ except 
C20:0, which was lower in YL compared to OO (P<0.01; Figure 2B).
Whole body substrate metabolism during exercise
Whole body energy expenditure during the last 10 min of 1 h of exercise at 50% VO2max 
was lower in OL and OO compared to YL (both P<0.05; Figure 3A), but the relative 
contribution from total fat oxidation to energy expenditure was similar (42.4 ± 3.1, 40.1 
± 4.6 and 43.9 ± 6.5%, respectively). Nevertheless, the oxidation of fat from sources other 
than plasma FFA (i.e. predominantly from IMCL) was almost 3-fold lower in OL and OO 
compared to YL (both P<0.05; Figure 3A), such that the relative contribution of these 
sources to total fat oxidation was around half that of YL (38.7 ± 7.7 and 45.0 ± 7.9 vs. 71.9 
± 3.1 %, respectively; P<0.01; Figure 3A). Plasma FFA Ra was similar between OL and OO 
(24.2 ± 2.9 vs. 24.3 ± 5.3 μmol·kg lbm-1·min-1), and greater compared to YL (13.8 ± 2.3 
μmol·kg lbm-1·min-1; P<0.05), but there were no differences in plasma FFA concentration 
(0.62 ± 0.06, 0.58 ± 0.09, and 0.45 ± 0.08 for OL, OO and YL, respectively). Plasma FFA 
Rd was also similar between OL and OO, but greater in OL compared to YL (P<0.05; Figure 
3B). In contrast, whereas the percentage of plasma FFA Rd oxidized was similar between 
OL and YL (54.4 ± 5.9 and 52.7 ± 3.4%, respectively; Figure 3C), it was lower in OO (42.2 
± 1.2%) compared to OL (P<0.05) and YL (P=0.07; Figure 3C).
From similar baseline concentrations, plasma norepinephrine increased to a similar steady-
state in OL and OO throughout 1 h of exercise, and was around 1.5-fold greater than the 
steady-state concentration achieved in YL (both P<0.05 respectively; Figure 3D). However, 
there were no differences between groups in baseline or steady-state plasma epinephrine 
(0.25 ± 0.02 to. 0.53 ± 0.11, 0.25 ± 0.06 to 0.34 ± 0.06, and 0.24 ± 0.04 to 0.43 ± 0.06 
nmol/L) or blood lactate (0.71 ± 0.06 to 1.50 ± 0.29, 0.97 ± 0.13 to 2.05 ± 0.31, and 0.87 
± 0.09 to 1.73 ± 0.28 mmol/L) concentrations in OL, OO and YL, respectively.
IMCL and skeletal muscle oxidative metabolism during exercise
The area of SSL region covered by LD was similar between OL and YL at rest and did not 
change during exercise (Figure 4A). However, SSL area covered by LD in OO was almost 3-
fold greater at rest compared with YL (P<0.05) and increased during exercise (P<0.05), such 
that post-exercise it was greater than both OL (P<0.05) and YL (P<0.01; Figure 4A). This 
was predominantly due to a 25% increase in average SSL LD size in OO (P=0.05; Figure 
4B). In contrast, exercise caused a decrease (P<0.01) in both the number of IMF LD (0.024 
± 0.001 to 0.017 ± 0.003, 0.022 ± 0.003 to 0.015 ± 0.002, and 0.023 ± 0.03 to 0.018 
± 0.003LD/μm2 for OL, YL and OO, respectively) and area covered by LD (Figure 4C). The 
latter was isolated to a 40% reduction in IMF area covered by LD in YL (0.05; Figure 4C). 
Average IMF LD size was 45% greater in OO compared to OL and YL post-exercise (both 
P<0.01; Figure 4D).
Resting skeletal muscle glycogen (Figure 5A), phosphocreatine (Figure 5B), and lactate 
(Figure 5C) content was similar between OL and YL and did not change measurably during 
exercise, whereas acetylcarnitine content increased during exercise by around 7 (P<0.001) 
and 3 fold (P<0.05), respectively. However, resting muscle glycogen and phosphocreatine 
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content were lower (P<0.05) and muscle lactate content more than doubled during exercise 
(P<0.05) in OO. Nevertheless, there were no significant differences in maximal CS (116.8 
± 12.6, 94.7 ± 8.8, and 84.1 ± 8.3 nmol·mg protein·-1min-1, respectively) or CPT1 (2.3 ± 0.3, 
1.8 ± 0.3, and 2.0 ± 0.1 nmol·mg protein·-1min-1, respectively) activities between OL, YL 
and OO, respectively, although the former tended to be greater in OL vs. OO (P=0.08).
Skeletal muscle gene expression
The relative expression of 12 skeletal muscle transcripts involved in fatty oxidation and 
IMCL turnover are presented in Table 2. HADHB and PLIN2 expression were greater in OL 
compared to YL (P<0.05), whereas ACACB, SPTLC1, and DGKD expression were lower in 
YL compared to OO (all P<0.05). Furthermore, PLIN2 gene expression was greater in OL 
vs. OO (P<0.05) respectively.
Discussion
Insulin resistance is closely related to IMCL accumulation, and both are associated with 
increasing age. However, it remains to be determined to what extent perturbations in IMCL 
metabolism are related to the ageing process per se or secondary to age-related changes in 
lifestyle. Thus, by matching young and older volunteers for body composition and self-
reported habitual physical activity levels the present study demonstrated that lean older 
individuals display comparable IMCL content and insulin sensitivity to their younger 
counterparts. On the other hand, ageing per se appeared to cause an exacerbated lipolytic 
response to exercise due, at least in part, to an increased sympathetic response. Coupled with 
increased adiposity and reduced habitual physical activity levels in an age-matched group 
this resulted in SSL IMCL accumulation, and may mechanistically help explain the 
association between increased IMCL and skeletal muscle insulin resistance in older 
individuals.
In line with several studies that suggest ageing per se does not cause insulin resistance (3, 4, 
5), there was no difference in whole-body glucose disposal, skeletal muscle 2DG6P 
accumulation, or the energy expenditure response during a euglycaemic hyperinsulinaemic 
clamp between old and young individuals matched for body composition and self-reported 
physical activity in the present study. Furthermore, the finding that whole-body and skeletal 
muscle insulin action was reduced in old overweight individuals with a similar lean body 
mass but lower self-reported physical activity supports the notion that lifestyle factors are 
more influential in the development of age-related insulin resistance (3, 4, 5, 39, 40, 41). A 
possible link between these factors and reduced skeletal muscle insulin sensitivity is the 
accumulation of SSL IMCL (9, 10) and associated lipid metabolites such as DAG and 
ceramide (13, 14, 15). Indeed, whereas there was no difference in SSL IMCL between lean 
old and young, SSL IMCL was more than 2-fold higher in the older overweight individuals, 
which is in agreement with a 2 and 3-fold greater content observed in lean sedentary older 
individuals (8) and type 2 diabetes (9), respectively. However, although the skeletal muscle 
content of the predominant DAG and ceramide species were not different between lean old 
and young they were also not greater in old overweight, with the exception of diC18:1 DAG 
and C20:0 ceramide. Indeed, total muscle DAG and ceramide do not correlate well with 
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insulin sensitivity but specific lipid species, particularly sarcolemmal saturated DAG, may 
influence insulin action (42).
Why IMCL accumulates, particularly in the SSL region, is not clear, but several studies have 
demonstrated reduced FFA oxidation in older individuals despite increased whole body 
lipolysis and FFA availability compared to young at rest and during exercise (17, 18). 
Indeed, although the relative contribution of fat oxidation to total energy expenditure during 
exercise was not different between the young and old groups of the present study, there was 
an elevated plasma norepinephrine, FFA Ra, and FFA Rd response to exercise at the same 
relative intensity observed in both the lean and overweight older individuals, suggesting an 
effect of age per se on whole body responses. This would fit with previous reports that age 
associated increments in norepinephrine are independent of habitual physical activity and 
likely due increased sympathetic activity rather than reduced norepinephrine clearance (43). 
As a consequence, the relative contribution of IMCL to fat oxidation was reduced in both old 
lean and overweight compared to young individuals. This is remarkable given there was 
presumably a greater lipolytic stimulus to IMCL by norepinephrine in the older individuals 
(44, 45), and would suggest a potent inhibitory effect of plasma derived FFA or a blunted 
contraction induced IMCL hydrolysis. Furthermore, a novel finding of the present study was 
that, assuming similar rates of adipose tissue FFA re-esterification (where FFA released from 
adipose tissue is reincorporated in a futile cycle), lean older individuals were able to oxidise 
a larger proportion of the excess FFA delivered during exercise compared to the older 
overweight individuals, where it deposited in SSL lipid droplets. This not only suggests that 
a more general, chronic imbalance between skeletal muscle FFA delivery and oxidation may 
contribute to IMCL accumulation, but also provides evidence for distinct roles of the 
localised IMCL pools. For example, the reduction in the number of IMF lipid droplets 
during exercise in the younger individuals suggests that this pool is used for muscle 
contraction, possibly in an ‘all or nothing’ fashion, whereas the deposition in the SSL pool 
suggests a role in buffering/trafficking of FFA influx (46), and perhaps insulin resistance. 
Interestingly, an improvement in insulin sensitivity has been previously observed with 
reduced SSL but not IMF IMCL following 10 to 12 weeks of exercise training where the 
capacity to oxidise FFA was increased (9, 10).
In addition to reduced energy expenditure, such as observed during insulin-stimulated 
conditions of the present study, several mechanisms may explain the apparent inability of 
skeletal muscle of older overweight men to oxidize excess FFA delivery. For example, it has 
been suggested that aging is associated with impaired in vivo (19) and in vitro (3, 20) 
skeletal muscle mitochondrial ATP production, as well as a reduction in mitochondrial 
content (8), independently of adiposity. However, there was no difference in skeletal muscle 
maximal CS activity, maximal and relative CPT1 activity, or phosphocreatine, glycogen, 
lactate, and acetylcarnitine metabolism during exercise between the lean old and young 
participants in the present study, all of which are markers of in vivo muscle oxidative 
capacity. On the other hand, the disparity between old lean and old overweight participants 
in the ability to oxidize excess fatty acids may be due to differences in partitioning of 
skeletal muscle lipid and a diversion of fatty acids from oxidation towards synthesis of 
IMCL and other lipid species. For example, older lean individuals had a greater mRNA 
expression of perilipin 2 (PLIN2), a lipid droplet bound protein involved IMCL hydrolysis, 
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and β-hydroxyacyl-CoA dehydrogenase (HADHB), an intramitochondrial enzyme that 
catalyses a rate-limiting step in β-oxidation, whereas old overweight had greater mRNA 
expression of acetyl-CoA carboxylase 2 (ACACB), which produces malonyl-CoA and 
inhibits CPT1, the rate limiting step for fatty acid entry into mitochondria. The PLIN2 
expression in particular would fit previous reports in overweight individuals of impaired 
IMCL turnover and FFA release toward mitochondrial oxidation (44, 47). Furthermore, old 
overweight had a greater expression of diacylglycerol kinase delta (DGKD), which 
phosphorylates diacylglycerol to produce phosphatidic acid, and serine palmitoyltransferase 
(SPTLC1), a rate-limiting step in ceramide synthesis, compared to young lean individuals. 
Both of these observations fit with the greater muscle content of some of the DAG and 
ceramide species in the present study. A similar gene expression pattern has also been 
previously observed in insulin resistant individuals (48), but how this translates into protein 
content/activity and whether it is cause or effect requires further investigation.
In conclusion, it is our assertion that increased IMCL (4, 8, 19) and reduced insulin 
sensitivity, mitochondrial capacity, and fat oxidation (3, 17, 18, 19, 20, 21, 49) often 
observed in older individuals are likely due to lifestyle factors rather than aging per se as 
commonly reported. However, age per se appears to increase the systemic sympathetic 
response to exercise and cause exacerbated adipose tissue lipolysis. Compounded by greater 
adiposity, the increased FA delivery appears to cause SSL IMCL accumulation in physically 
inactive older individuals. Thus, targeted strategies to reduce muscle lipid delivery and 
improve adipose tissue function may be warranted, particularly as physical inactivity 
appears to worsen the inability to suppress adipose tissue lipolysis in older individuals (50).
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Figure 1. 
Insulin sensitivity index (A), skeletal muscle 2-deoxyglucose-6-phosphate accumulation (B), 
plasma 2-deoxyglucose concentration (C), and whole-body energy expenditure (D) during a 
3 h hyperinsulinaemic (60mU m-2 min-1) euglycaemic clamp in young lean (YL, white 
squares), old lean (OL, black circles), and old overweight (OO, white circles) males. Values 
represent mean ± SEM (n=7). *P<0.05, ** P<0.01, OO different to corresponding YL 
value. †P<0.05, ††P<0.01, OO different to corresponding OL value. ^P<0.05, ^^P<0.01, 
different to corresponding baseline value.
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Figure 2. 
Fasting skeletal muscle diacylglycerol (A) and ceramide content (B) in young lean (white 
bars), old lean (black bars), and old overweight (hatched bars) males. Values represent mean 
± SEM (n=7). *P<0.05, old overweight different to corresponding young lean 
value. †P<0.05, old overweight different to corresponding old lean value.
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Figure 3. 
Whole-body energy expenditure (A), plasma FFA rate of disappearance (Rd; B), percentage 
of plasma FFA Rd oxidised (C), and plasma noradrenaline concentration (D) during 1 h of 
cycling exercise at 50% VO2max in young lean (YL, white squares), old lean (OL, black 
circles), and old overweight (OO, white circles) males. The contribution of IMCL to whole-
body energy expenditure in 3A assumes non-plasma FFA oxidation is predominantly IMCL. 
Values represent mean ± SEM (n=7). *P<0.05, ** P<0.01, OO different to corresponding 
YL value. +P<0.05, ++P<0.01, OL different to corresponding YL value.
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Figure 4. 
Percentage area of subsarcolemmal (SSL) region covered by lipid droplets (LD; A), average 
SSL LD size (B), percentage area of intermyofibrillar (IMF) region covered by LD (C), and 
average IMF LD size (D) from electron micrographs of skeletal muscle samples taken before 
(pre exercise) and after (post exercise) 1 h of cycling exercise at 50% VO2max in young lean 
(white bars), old lean (black bars), and old overweight (hatched bars) males. Values 
represent mean ± SEM (n=7). *P<0.05, ** P<0.01, old overweight different to 
corresponding young lean value. †P<0.05, ††P<0.01, old overweight different to 
corresponding old lean value. ^P<0.05, different to corresponding pre exercise value.
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Figure 5. 
Skeletal muscle glycogen (A), phosphocreatine (B), lactate (C), and acetylcarnitine (D) 
content before (pre exercise) and after (post exercise) 1 h of cycling exercise at 50% 
VO2max in young lean (white bars), old lean (black bars), and old overweight (hatched bars) 
males. Values represent mean ± SEM (n=7). *P<0.05, old overweight different to 
corresponding young lean value. †P<0.05, old overweight different to corresponding old lean 
value. ^P<0.05, ^^^P<0.001, different to corresponding pre exercise value.
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Table 1
Characteristics of young lean (YL), old lean (OL), and old overweight (OO) male participants.
YL OL OO
n 7 7 7
Age (y) 21.5 ± 1.0 69.7 ± 0.9+++ 68.6 ± 0.8***
Statin use (n) 0 3 4
Body mass (kg) 71.8 ± 3.6 70.3 ± 2.4 86.3 ± 1.8***,†††
BMI (kg/m2) 22.4 ± 0.7 24.0 ± 0.6 29.0 ± 0.7***,†††
Lean mass (lbm; kg) 55.9 ± 3.2 51.3 ± 1.5 55.6 ± 1.9
Arm lean mass (kg) 7.6 ± 0.4 6.7 ± 0.3 7.4 ± 0.3
Leg lean mass (kg) 21.8 ± 0.4 18.3 ± 0.6 19.6 ± 0.7
Trunk fat mass (kg) 4.6 ± 0.8 7.2 ± 1.1 16.0 ± 0.8***,†††
Arm fat (kg) 0.9 ± 0.1 1.5 ± 0.2 2.6 ± 0.3***,†††
Leg fat (kg) 4.7 ± 0.4 4.9 ± 0.4 7.4 ± 0.6†
Fasting blood glucose (mmol/L) 4.5 ± 0.1 4.7 ± 0.1 5.0 ± 0.1*
Fasting serum insulin (mU/L) 10.6 ± 1.4 7.4 ± 1.6 12.6 ± 1.2†
HOMA IR 2.14 ± 0.32 1.60 ± 0.36 2.81 ± 0.25†††
Physical activity frequency (occasions/week) 3.5 ± 0.5 5.1 ± 1.2 1.8 ± 0.7†
VO2max (L/min) 3.19 ± 0.19 2.26 ± 0.15+++ 2.19 ± 0.13***
VO2max (mL·kg lbm-1·min-1) 57.4 ± 2.4 44.6 ± 1.9+++ 39.9 ± 1.5***
Workload at 50% VO2max (W) 93.0 ± 5.9 55.9 ± 5.8+++ 46.3 ± 6.7***
Heart rate at 50% VO2max (beats/min) 137 ± 2 102 ± 7+++ 102 ± 6***
All values (n=7) are means ± standard error of the mean (SEM).
***
P<0.001, OO different to corresponding YL value.
†
P<0.05
†††
P<0.001, OO different to corresponding OL value.
+++
P<0.001, OL different to corresponding YL value.
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Table 2
Expression of skeletal muscle transcripts encoding proteins involved in fatty acid oxidation and IMCL in 
young lean (OO), old lean (OL), and old overweight (OO) males.
Gene YL OL OO
Fatty acid oxidation ACACB 0.79 ± 0.04 0.83 ± 0.24 1.38 ± 0.12*†
CPT1B 1.01 ± 0.25 3.38 ± 1.38 1.76 ± 0.44
CPT2 0.83 ± 0.07 0.90 ± 0.18 1.02 ± 0.17
HADHB 0.70 ± 0.07 1.33 ± 0.22+ 0.83 ± 0.14†
ACADM 0.57 ± 0.08 0.73 ± 0.04 0.63 ± 0.08
ACATI 0.55 ± 0.09 0.74 ± 0.10 0.66 ± 0.09
IMCL turnover SPTLC1 0.81 ± 0.09 1.19 ± 0.21 1.29 ± 0.12*
DGKD 1.05 ± 0.11 1.15 ± 0.24 1.59 ± 0.13*
DGAT1 0.87 ± 0.06 1.00 ± 0.13 1.12 ± 0.08
PLIN2 1.15 ± 0.10 1.98 ± 0.30+ 1.24 ± 0.16†
PLIN5 0.93 ± 0.22 1.24 ± 0.26 1.24 ± 0.28
PNPLA2 0.74 ± 0.07 0.63 ± 0.16 0.62 ± 0.08
All values (n=7) are means ± standard error of the mean (SEM) and expressed as relative mRNA abundance compared to a YL comparator.
*
P<0.05, OO different to corresponding YL value.
†
P<0.05, OO different to corresponding OL value.
+
P<0.05, OL different to corresponding YL value.
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